Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855487 | 1.00 | KDM4E (0.34) | KDM4EKMT2ACYP2D6SYKFFAR3 | |
| SCHEMBL3296868 | 1.00 | KDM4E (0.34) | KDM4EKMT2ACYP2D6SYKFFAR3 | |
| SCHEMBL27177215 | 0.88 | HSD17B10 (0.32) | — | |
| SCHEMBL1468789 | 0.88 | HSD17B10 (0.32) | — | |
| SCHEMBL1710564 | 0.87 | KDM4E (0.41) | KDM4EKMT2ACYP2D6FFAR3 | |
| Hydrochloric Acid SCHEMBL17748973 | 0.85 | KDM4E (0.39) | KDM4EKMT2AFFAR3 | |
| SCHEMBL19613078 | 0.83 | KDM4E (0.34) | KDM4EKMT2AFFAR3 | |
| SCHEMBL3199698 | 0.83 | KDM4E (0.34) | KDM4EKMT2AFFAR3 | |
| SCHEMBL4783196 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL14828866 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| WO-2024107686-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023235618-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| EP-3953356-B1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3953356-A1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-02-16 | — | — | EP | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021099285-A1 | TRIAZATRICYCLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-27 | — | — | WO | disclosed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020207991-A1 | HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-10-15 | — | — | WO | disclosed |
| CN-103492377-B | As the triazolopyridine compounds of PIM kinase inhibitor | ARRAY BIOPHARMA INC. (US) | 2016-04-20 | — | — | CN | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1945646-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Cellzome (UK) Ltd. (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | HRH4, HRH3, HRH2 | KDM4E 1688/4885KMT2A 1030/4885CYP2D6 1265/4885 |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | KDM4E 3799/4885KMT2A 2174/4885CYP2D6 1107/4885 |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | PTPN1, PTPN9, PTPN7 | KDM4E 648/4885KMT2A 1327/4885CYP2D6 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.